ClinicalTrials.gg
Not yet recruitingNCT07544160Updated Apr 22, 2026

BCMA-CD19 cCAR T for the Treatment of Refractory Inflammatory Bowel Disease (IBD)

A Phase 1/2 interventional study of ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T in Inflammatory Bowel Diseases (IBD), sponsored by iCell Gene Therapeutics. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by iCell Gene Therapeutics · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 112 studies in Inflammatory Bowel Diseases with a site in China — 49 open to participants now, 53 under way, 5 of them phase 3. Inflammatory Bowel Diseases · China.

Planned enrollment
56th of 58
18 · median 97
Started
2026
with 8 others
Phase 1/2
Only one
of the 112
Primary completion
2028-04
later than 43 of 52 live
Registered
103rd of 112
by date

Among the 112 studies in Inflammatory Bowel Diseases with a site in China, this one is the 56th largest by planned enrollment of the 58 interventional ones that give a count, is one of 9 that started in 2026, is the only one in phase 1/2, reaches primary completion later than 43 of the 52 other live ones, and was the 103rd registered.

Inflammatory Bowel Diseases

1,550 studies on the registry are indexed under Inflammatory Bowel Diseases; 424 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

49 of the 112 studies in Inflammatory Bowel Diseases with a site in China are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 133 (48%) set no upper age limit and 116 (42%) stop at 75 or younger; 76 take children under 18; 61 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 112 studies in Inflammatory Bowel Diseases with a site in China, or all of them as a file.
02

Study summary

This is a Phase I, IIa, Single-Arm, interventional, open label, treatment study to evaluate the safety and tolerability of ICG318 CAR-T (BCMA-CD19-IL-15/IL15sushi cCAR T cells) in patients with relapsed and/or refractory inflammatory bowel disease.

Read the detailed description

Inflammatory bowel disease (IBD) is a chronic, immune-mediated disease of the gastrointestinal (GI) tract. IBD may result in GI lesions as well as extraintestinal manifestations affecting the joints, skin, eyes, and biliary system. IBD is driven by humoral immune cells including B cells, plasma cells and long-lived plasma cells.

ICG318 CAR-T, the investigational agent in this clinical trial, is an armored, compound chimeric antigen receptor (cCAR) composed of two independently functioning CARs that target the CD19 surface antigen and the BCMA surface antigen on B cells and plasma/long-lived plasma cells, respectively.

This study is being conducted to evaluate the safety and efficacy of ICG318 CAR-T in patients with refractory IBD. A single dose of ICG318 CAR-T will be evaluated after cyclophosphamide and fludarabine lymphodepletion.

03

Conditions studied

  • Inflammatory Bowel Diseases (IBD)

Keywords

  • Ulcerative Colitis
  • Crohn's disease
  • Inflammatory Bowel Disease
  • IBD
  • UC
  • CD
  • CAR-T
  • Cellular Therapy
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion criteria:

  1. All subjects or legal guardians must sign an ethics committee-approved form in writing prior to initiation of any screening procedures.
  2. Male or female subject over 18 years old and under 70 years old at the time of evaluation; Weight ≥ 40 kg.
  3. Diagnosed with inflammatory bowel disease assessed by the investigator and the disease course has been ≥ 3 months before signing informed consent (clinical manifestations, endoscopy and histopathological reports consistent with the diagnosis of inflammatory bowel disease are required).
  4. The subject has documented inadequate response, loss of response, or intolerance to at least one advanced therapy for IBD.
  5. Patients with IBD during the screening period need to meet the requirements of moderate to severe IBD; UC: active ulcerative colitis, defined as per the adapted Mayo score criteria. CD: CD subjects with moderate to severe active CD, defined as interpreted by SES-CD.
  6. greater than 6 months;
  7. Female individuals with fertility (defined as all females who are physiologically capable of becoming pregnant) must provide informed consent, have a negative blood pregnancy test result, and agree to use highly effective from the time of informed consent until 1 year after CAR-T cell infusion. Male individuals with fertility must agree to use effective barrier contraception from the time of informed consent until 1 year after CAR-T cell infusion, and should not donate semen or sperm during the entire study period.
  8. Indeterminate colitis is permitted.

Key Exclusion criteria:

  1. Subjects who have previously received any BCMA and/or CD19 targeted cell therapy products or CAR-T therapy for any target before signing the informed consent form.
  2. Undiagnosed type colitis, fulminant colitis, Hirschsprung-associated enterocolitis (HAEC), microscopic colitis, ischemic colitis, radiation colitis, colitis-related diverticular disease, or other colitis or enteritis type that may confound the evaluation of efficacy.
  3. Subjects with malignant tumors or dysplasia on endoscopy.
  4. Subjects with severely impaired vital organ function.
  5. Impaired bone marrow function.
  6. Active , positive, antibody positive, Treponema pallidum antibody positive, Active tuberculosis.
  7. Presence of any IBD related complications determined by the investigator to interfere with the study of ICG318 CAR-T in IBD.
  8. History of bleeding within 30 days determined by the investigator to exclude the patient.
  9. Infectious diseases: subjects with acute, life-threatening bacterial, viral or fungal infections that have not been controlled.
  10. Hospitalization for IBD-related complications within 30 days prior to screening.

11) central nervous system disease determined by the investigator to impair the subjects ability to participate safely in this trial.

12) Subjects with prior or concurrent . Exceptions may be determined at the discretion of the investigator.

13) Vaccination within 30 days before screening and vaccination within 3 months after planned cell ICG318 CAR-T infusion.

14) Subjects who are receiving or have received another drug or drugs without adequate time as determined by the principal investigator.

15) Those who are judged by the investigator to be unfit for leukapheresis, or whose IBD disease severity and trajectory are not compatible with infusion with ICG318 CAR-T cells, or any critical steps of the trial evaluation such as but not limited to to colonoscopy.

16) Female subjects who are pregnant or lactating. 17) diseases judged by the investigator to require systemic treatment and affect the evaluation of efficacy.

18) Suicidal tendencies, tobacco use, substance use, or alcohol abuse as determined by the investigator.

19) Those who have a history of a severe drug allergy, or are allergic to the test drug ingredients, or combined therapeutic drugs.

20) Other conditions that the investigator believes should not participate in this clinical trial.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Single Arm Biologic Infusion

    Biological: ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T

Interventions

  • BiologicalICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T

    Anti-BCMA, Anti-CD19 Compound CAR-T cells

06

What researchers measure

Primary outcomes

  1. Number of Adverse Events (AEs) after ICG318 CAR-T infusion.

    Number of participants with AEs, Serious Adverse Events (SAEs), Treatment Emergent Adverse Events (TEAEs), Adverse Events of Special Interest (AESI), and Dose Limiting Toxicities (DLTs).

    Time frame: Starting day 0 and up to 2 years after ICG318 CAR-T infusion.

Secondary outcomes

  1. Determine the recommended phase 2 dose (RP2D) regimen.

    The protocol is based on cohort schema with dose escalation from 1×10\^6/kg to 4×10\^6/kg.

    Time frame: Starting day 0 and assessed 2 years after ICG318 CAR-T infusion.

  2. The proportion of subjects who achieved drug-free remission.

    Clinical, endoscopic, and histological remission maintained without any IBD-directed therapy.

    Time frame: At 6 months, 12 months, 24 months after ICG318 CAR-T infusion.

  3. Fecal calprotectin levels.

    Time frame: 28 days, 2 months, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months after ICG318 CAR-T infusion.

  4. Cmax

    Maximum serum concentration of ICG318 CAR-T.

    Time frame: Assessed as per schedule of events up to 2 years after ICG318 CAR-T infusion.

  5. Tmax

    Time to maximum serum concentration of ICG318 CAR-T.

    Time frame: Assessed as per schedule of events up to 2 years after ICG318 CAR-T infusion.

  6. T1/2

    Half-life of ICG318 CAR-T serum concentration.

    Time frame: Assessed as per schedule of events up to 2 years after ICG318 CAR-T infusion.

  7. AUC

    Plasma ICG318 CAR-T concentration versus time. Total systemic exposure to ICG318 CAR-T over time.

    Time frame: Assessed as per schedule of events up to 2 years after ICG318 CAR-T infusion.

  8. Rate of B cell elimination and naïve B-Cell recovery

    B cell subsets will be assessed by flow cytometry panels and B-Cell receptor sequencing.

    Time frame: Assessed as per schedule of events up to 2 years after ICG318 CAR-T infusion.

  9. Recovery of immunoglobulins

    Immunoglobulins IgG, IgM and IgA levels.

    Time frame: Assessed as per schedule of events up to 2 years after ICG318 CAR-T infusion.

  10. The proportion of subjects who achieved clinical remission from Crohn's Disease (CD)

    CD activity index (CDAI) remission

    Time frame: 3 months, 6 months, 12 months, 18 months, 24 months after ICG318 CAR-T infusion.

  11. The proportion of subjects who achieved clinical response from CD

    CDAI reduction

    Time frame: 3 months, 6 months, 12 months, 18 months, 24 months after ICG318 CAR-T infusion.

  12. The proportion of subjects who achieved endoscopic remission from CD

    SES-CD remission.

    Time frame: 12 months, 24 months after ICG318 CAR-T.

  13. The proportion of subjects who achieved endoscopic response from CD

    SES-CD reduction

    Time frame: 12 months, 24 months after ICG318 CAR-T.

  14. Histological Remission from CD

    Absence of inflammation on tissue samples collected from endoscopic biopsy.

    Time frame: 12 months, 24 months after ICG318 CAR-T.

  15. The proportion of subjects who achieved clinical remission from Ulcerative Colitis (UC)

    Adapted Mayo score remission.

    Time frame: 3 months, 6 months, 12 months, 18 months, 24 months after ICG318 CAR-T infusion.

  16. The proportion of subjects who achieved clinical response from UC

    Adapted Mayo score response.

    Time frame: 3 months, 6 months, 12 months, 18 months, 24 months after ICG318 CAR-T infusion.

  17. The proportion of subjects who achieved endoscopic remission from UC

    Mayo Endoscopic Subscore (MES) remission.

    Time frame: 12 months, 24 months after ICG318 CAR-T infusion.

  18. The proportion of subjects who achieved endoscopic response from UC

    MES response.

    Time frame: 12 months, 24 months after ICG318 CAR-T infusion.

  19. Histological remission from UC

    Nancy Histological Index (NHI) scoring. Evaluation performed on tissue samples collected from endoscopic biopsy.

    Time frame: 12 months, 24 months after ICG318 CAR-T infusion.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2026; primary completion for Apr 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2026
First posted
Apr 22, 2026
StartEst.
Apr 7, 2026
Primary completionEst.
Apr 7, 2028
CompletionEst.
Apr 7, 2028
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07544160
Lead sponsor
iCell Gene Therapeutics
Collaborators
iCAR Bio Therapeutics Ltd.
Responsible party
Sponsor
First posted
Apr 22, 2026
Start date
Apr 7, 2026 (estimated)
Primary completion
Apr 7, 2028 (estimated)
Completion
Apr 7, 2028 (estimated)
Last update
Apr 22, 2026

Study contacts

Kevin Pinz, MS
Contact
kevin.pinz@icellgene.com
6315386218

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion